MARKET

QLGN

QLGN

Qualigen Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.590
+0.060
+3.92%
After Hours: 1.640 +0.05 +3.14% 18:20 05/14 EDT
OPEN
1.580
PREV CLOSE
1.530
HIGH
1.650
LOW
1.530
VOLUME
922.94K
TURNOVER
--
52 WEEK HIGH
19.75
52 WEEK LOW
1.510
MARKET CAP
45.84M
P/E (TTM)
-0.4593
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers
Benzinga · 2h ago
Qualigen Therapeutics EPS beats by $0.01, beats on revenue
Qualigen Therapeutics (QLGN): Q1 GAAP EPS of -$0.13 beats by $0.01.Revenue of $1.9M (+111.1% Y/Y) beats by $0.7M.As of March 31, 2021, Qualigen Therapeutics had $21.9 million of cash and
Seekingalpha · 2h ago
BRIEF-Qualigen Therapeutics Reports First Quarter 2021 Financial Results
reuters.com · 4h ago
Qualigen Therapeutics, Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update
Conference call scheduled for May 18, 2021 at 4:10 p.m. EDT.
GlobeNewswire · 5h ago
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13)
Benzinga · 10h ago
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11)
Benzinga · 2d ago
Stocks That Hit 52-Week Lows On Tuesday
    Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows.
Benzinga · 3d ago
QLGN: IND Filing for QN-165 as COVID-19 Treatment Expected in 2Q21
Qualigen Therapeutics, Inc. (NASDAQ:QLGN) is developing QN-165 (formerly AS1411) as a treatment for COVID-19. In October 2020, the company completed a positive pre-IND meeting with the U.S. FDA regarding QN-165’s development pathway.
Zacks Small Cap Research · 04/26 11:28
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of QLGN. Analyze the recent business situations of Qualigen Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average QLGN stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 46
Institutional Holdings: 2.07M
% Owned: 7.19%
Shares Outstanding: 28.83M
TypeInstitutionsShares
Increased
7
184.11K
New
5
212.27K
Decreased
2
32.32K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.85%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Chairman/President/Chief Executive Officer/Director
Michael Poirier
Chief Financial Officer/Vice President - Finance
Christopher Lotz
Chief Operating Officer/Vice President/Secretary
Shishir Sinha
Executive Vice President/Director
Amy Broidrick
Chief Scientific Officer/Vice President - Research & Development
Wajdi Abdul-Ahad
Director
Ira Ritter
Independent Director
Richard David
Independent Director
Sidney Emery
Independent Director
Matthew Korenberg
Independent Director
Kurt Kruger
No Data
  • All
  • Financials
  • Insiders
More
About QLGN
Qualigen Therapeutics, Inc., formerly Ritter Pharmaceuticals, Inc., is a biotechnology company. The Company is focused on the development and commercialization of therapeutic products for the treatment of cancer and infectious diseases, as well as development of its FastPack diagnostic platform. Its pipeline includes AS1411, Aptamer Linked Anti Nucleolin (ALAN), Aptamer Linked Anti Nucleolin - Contrast Enhancement (ALAN-CE), Aptamer Linked Anti Nucleolin - Radiation Enhancement (ALAN-RE), Selective Target Antigen Removal System (STARS) and RAS-F. The FastPack System is an immunoassay testing system, which consists of the FastPack Analyzer and the FastPack test pouch, a single-use, disposable, foil packet which includes the FastPack reagent chemistry. The Company’s subsidiary is Qualigen, Inc.

Webull offers kinds of Qualigen Therapeutics Inc stock information, including NASDAQ:QLGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QLGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading QLGN stock methods without spending real money on the virtual paper trading platform.